Shanghai MicroPort MedBot (Group) Co., Ltd. provided group earnings guidance for the year ended December 31, 2023. The Board expected that the revenue of the Company for the year ended 31 December 2023 will achieve a year-on-year growth of over 350% as compared to that for the year ended 31 December 2022, which is mainly attributable to the continuous growth in sales revenue from the full-scale commercialisation of the Group's products, namely Toumai Laparoscopic Surgical Robot, SkyWalker Joint Replacement Surgical Robot and DFVision 3D Electronic Laparoscope. The Board expected that the company will record a net loss of not more than RMB 1,050 million for the year ended 31 December 2023 (for the year ended 31 December 2022: RMB 1,146 million).

The decrease in the expected net loss is mainly attributable to (i) an increase in gross profit driven by the growth of revenue; and (ii) a decrease in research and development ("R&D") expenses with the enhancement of R&D efficiency through focusing on core R&D projects.